This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Diazoxide tablets

Updated 2 Feb 2023 | Hypoglycaemia


Oral formulations containing diazoxide

Drugs List

  • diazoxide 50mg tablets
  • EUDEMINE 50mg tablets
  • Therapeutic Indications


    Intractable hypoglycaemia

    Unlicensed Uses

    Resistant hypertension



    Initial dose: 5mg/kg daily divided in two or three doses.
    Maintenance dose: 3mg/kg to 8mg/kg daily divided in two or three doses.

    Hypoglycaemia in patients with benign or malignant islet cell tumours
    Doses up to 1g daily have been used. These patients may require larger doses than normal.


    Initial dose: 5mg/kg daily divided in two or three doses.
    Maintenance dose: 3mg/kg to 8mg/kg daily divided in two or three doses.

    The following alternative dosing schedule may be suitable:
    Initial dose: 1.7mg/kg three times daily.
    Maintenance dose: 1.5mg/kg to 3mg/kg two to three times daily. Doses up to 5mg/kg three times daily may be required.

    Leucine sensitive hypoglycaemia
    15mg/kg to 20mg/kg daily.

    Resistant hypertension (unlicensed)
    Initial dose: 1.7mg/kg three times daily.
    Maintenance dose: 1.7mg/kg to 5mg/kg three times daily.


    Hypoglycaemia (unlicensed)
    Initial dose: 5mg/kg twice daily. Dose should then be titrated according to response.
    Maintenance dose: 1.5mg/kg to 3mg/kg two to three times daily. Doses up to 7mg/kg three times daily may be required.

    Resistant hypertension (unlicensed)
    Initial dose: 1.7mg/kg three times daily.
    Maintenance dose: 1.7mg/kg to 5mg/kg three times daily.



    Precautions and Warnings

    Left-to-right cardiovascular shunt
    Aortic stenosis
    Cardiac failure
    Cerebrovascular disorder
    Coarctation of the aorta
    History of gout
    Ischaemic heart disease
    Poor cardiac reserve
    Reduced serum proteins
    Renal impairment
    Right-to-left cardiovascular shunt

    May cause hypokalaemia - give potassium replacement therapy
    Assess growth, bone and psychological maturation regularly in children
    Maintain urine output in excess of 1 litre/day in severe renal impairment
    Monitor blood glucose
    Monitor blood pressure regularly
    Monitor uric acid levels
    Patients with fluid retention should be treated with diuretics
    Perform regular white blood cell and platelet counts
    Increased risk of hypotension with diuretics and other antihypertensives
    Consider dose reduction in renal impairment

    Retention of sodium and water is likely thus patients may need to be treated with an oral diuretic such as furosemide (up to 1 g daily). It must be expected that if diuretics are administered then both the hypotensive and hyperglycaemic actions of diazoxide will be potentiated, thus the dosage of diazoxide will require adjustment downwards.

    Use with caution in patients in whom sodium and water retention may worsen or precipitate congestive heart failure, e.g. cardiac failure or impaired cardiac reserve. Such retention may have a direct effect on cardiac function.

    The very rapid, almost complete protein binding of diazoxide requires careful dosage consideration in patients whose plasma proteins may be lower than normal.

    Pregnancy and Lactation


    Use diazoxide with caution during pregnancy.

    Diazoxide also inhibits uterine activity during labour. The degree and duration of inhibition is dose dependant (Briggs, 2015).

    Although it has been used to treat severe hypertension in pregnancy, there are safer alternatives and the long term effect on the infant has not been evaluated. Diazoxide is known to cross the placenta readily and foetal plasma concentrations reach levels similar to maternal levels. If diazoxide is necessary during pregnancy, small doses should be used (Briggs, 2015).

    The use of oral diazoxide in the last 19 to 69 days of pregnancy has been associated with alopecia, hypertrichosis lanuginosa and decreased ossification of the wrist in the neonate (Briggs, 2015).

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use of diazoxide is contraindicated during breastfeeding.

    At the time of writing there was insufficient information to assess the effect/s of diazoxide on a breast feeding infant.

    Briggs (2015) suggests that the molecular weight (about 231) is low enough that passage into milk should be expected.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal pain
    Blurred vision
    Cardiac failure
    Cataracts (transient)
    Cogwheel rigidity
    Decrease in creatinine clearance
    Decrease in haemoglobin and haematocrit
    Extrapyramidal effects
    Fluid retention
    Hyperosmolar non-ketotic coma
    Hypersensitivity reactions
    Immunoglobulin abnormalities
    Increase in alkaline phosphatase
    Increase in AST level
    Increased serum androgens
    Lichenoid rash
    Musculoskeletal pain
    Nephrotic syndrome
    Oculogyric crisis
    Parkinsonian tremor
    Pulmonary hypertension
    Reduced libido
    Sodium retention
    Subconjunctival haemorrhage
    Taste disturbances
    Visual disturbances
    Voice changes


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2017

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Summary of Product Characteristics: Eudemine 50mg Tablets. RPH Pharmaceuticals AB. Revised May 2015.

    NICE - Evidence Services
    Available at:
    Last accessed: 28 June 2017.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.